Japanese trial of Gamma-delta T cell therapy

Medinet has signed a joint research agreement with two medical institutions, the Japanese Red Cross Medical Center and the Shin-Yokohama Medical Clinic.

The three partners will jointly undertake through March 2006 clinical studies of lymphokine-activated killer cell therapy using gamma-delta T cells. Specifically, they aim to verify the safety and validity of cell therapy in treating multiple myeloma.